Genesis R&D Finalizes Terms of Investment Deal for New Subsidiary

According to the company, an unnamed Japanese investment firm has agreed to provide up to NZ$1 million ($672,000) in funding to the subsidiary, which will develop Genesis' single-stranded RNAi technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.